Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study - PubMed (original) (raw)
Clinical Trial
. 2006 Nov;63(11):1545-50.
doi: 10.1001/archneur.63.11.1545.
Affiliations
- PMID: 17101822
- DOI: 10.1001/archneur.63.11.1545
Clinical Trial
Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study
Ernst J Schaefer et al. Arch Neurol. 2006 Nov.
Abstract
Background: Docosahexaenoic acid (DHA) is an abundant fatty acid in the brain. In the diet, DHA is found mostly in fatty fish. The content of DHA has been shown to be decreased in the brain and plasma of patients with dementia.
Objective: To determine whether plasma phosphatidylcholine (PC) DHA content is associated with the risk of developing dementia.
Design, setting, and participants: A prospective follow-up study in 899 men and women who were free of dementia at baseline, had a median age of 76.0 years, and were followed up for a mean of 9.1 years for the development of all-cause dementia and Alzheimer disease.
Main outcome measures: Plasma PC fatty acid levels were measured at baseline. Cox proportional regression analysis was used to assess relative risks of all-cause dementia and Alzheimer disease according to baseline plasma levels.
Results: Ninety-nine new cases of dementia (including 71 of Alzheimer disease) occurred during the follow-up. After adjustment for age, sex, apolipoprotein E epsilon4 allele, plasma homocysteine concentration, and education level, subjects in the upper quartile of baseline plasma PC DHA levels, compared with subjects in the lower 3 quartiles, had a relative risk of 0.53 of developing all-cause dementia (95% confidence interval, 0.29-0.97; P=.04) and 0.61 of developing Alzheimer disease (95% confidence interval, 0.31-1.18; P=.14). Subjects in the upper quartile of plasma PC DHA levels had a mean DHA intake of 0.18 g/d and a mean fish intake of 3.0 servings per week (P<.001) in a subset of 488 participants. We found no other significant associations.
Conclusion: The top quartile of plasma PC DHA level was associated with a significant 47% reduction in the risk of developing all-cause dementia in the Framingham Heart Study.
Comment in
- Docosahexaenoic acid and Alzheimer disease.
Morris MC. Morris MC. Arch Neurol. 2006 Nov;63(11):1527-8. doi: 10.1001/archneur.63.11.1527. Arch Neurol. 2006. PMID: 17101820 Review. No abstract available.
Similar articles
- Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG. Graff-Radford NR, et al. Arch Neurol. 2007 Mar;64(3):354-62. doi: 10.1001/archneur.64.3.354. Arch Neurol. 2007. PMID: 17353377 - Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment.
Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Conquer JA, et al. Lipids. 2000 Dec;35(12):1305-12. doi: 10.1007/s11745-000-0646-3. Lipids. 2000. PMID: 11201991 - Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study.
Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D, Gibney MJ. Tully AM, et al. Br J Nutr. 2003 Apr;89(4):483-9. doi: 10.1079/BJN2002804. Br J Nutr. 2003. PMID: 12654166 - Docosahexaenoic acid homeostasis, brain aging and Alzheimer's disease: Can we reconcile the evidence?
Cunnane SC, Chouinard-Watkins R, Castellano CA, Barberger-Gateau P. Cunnane SC, et al. Prostaglandins Leukot Essent Fatty Acids. 2013 Jan;88(1):61-70. doi: 10.1016/j.plefa.2012.04.006. Epub 2012 May 9. Prostaglandins Leukot Essent Fatty Acids. 2013. PMID: 22575581 Review. - Ageing and apoE change DHA homeostasis: relevance to age-related cognitive decline.
Hennebelle M, Plourde M, Chouinard-Watkins R, Castellano CA, Barberger-Gateau P, Cunnane SC. Hennebelle M, et al. Proc Nutr Soc. 2014 Feb;73(1):80-6. doi: 10.1017/S0029665113003625. Epub 2013 Oct 9. Proc Nutr Soc. 2014. PMID: 24103099 Review.
Cited by
- Hydroxyurea-induced membrane fluidity decreasing as a characterization of neuronal membrane aging in Alzheimer's disease.
Yu Q, Cheng X. Yu Q, et al. Aging (Albany NY). 2021 May 11;13(9):12817-12832. doi: 10.18632/aging.202949. Epub 2021 May 11. Aging (Albany NY). 2021. PMID: 33972461 Free PMC article. - Omega-3 fatty acids: potential role in the management of early Alzheimer's disease.
Jicha GA, Markesbery WR. Jicha GA, et al. Clin Interv Aging. 2010 Apr 7;5:45-61. doi: 10.2147/cia.s5231. Clin Interv Aging. 2010. PMID: 20396634 Free PMC article. Review. - Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.
Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS. Quinn JF, et al. JAMA. 2010 Nov 3;304(17):1903-11. doi: 10.1001/jama.2010.1510. JAMA. 2010. PMID: 21045096 Free PMC article. Clinical Trial. - Tart Cherry Extract and Omega Fatty Acids Reduce Behavioral Deficits, Gliosis, and Amyloid-Beta Deposition in the 5xFAD Mouse Model of Alzheimer's Disease.
Bowers Z, Maiti P, Bourcier A, Morse J, Jenrow K, Rossignol J, Dunbar GL. Bowers Z, et al. Brain Sci. 2021 Oct 27;11(11):1423. doi: 10.3390/brainsci11111423. Brain Sci. 2021. PMID: 34827424 Free PMC article. - Behavioral and Physical Activity Interventions for HAND.
Montoya JL, Henry B, Moore DJ. Montoya JL, et al. Curr Top Behav Neurosci. 2021;50:479-501. doi: 10.1007/7854_2018_79. Curr Top Behav Neurosci. 2021. PMID: 30694458 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical